Hepion Pharmaceuticals (NASDAQ:HEPA) Trading 7.6% Higher

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA – Get Rating) traded up 7.6% during trading on Monday . The company traded as high as $7.09 and last traded at $7.09. 8,338 shares changed hands during trading, a decline of 73% from the average session volume of 30,505 shares. The stock had previously closed at $6.59.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Brookline Capital Management restated a “buy” rating on shares of Hepion Pharmaceuticals in a research report on Tuesday, January 31st. Alliance Global Partners assumed coverage on Hepion Pharmaceuticals in a research report on Monday, January 23rd. They set a “buy” rating on the stock.

Hepion Pharmaceuticals Stock Performance

The firm has a market capitalization of $25.27 million, a P/E ratio of -0.56 and a beta of 1.63. The stock has a 50-day moving average of $13.83 and a 200 day moving average of $12.20.

Institutional Investors Weigh In On Hepion Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC increased its stake in shares of Hepion Pharmaceuticals by 15.8% in the 1st quarter. Renaissance Technologies LLC now owns 284,300 shares of the company’s stock valued at $221,000 after buying an additional 38,700 shares during the period. BlackRock Inc. increased its stake in shares of Hepion Pharmaceuticals by 0.3% in the 1st quarter. BlackRock Inc. now owns 1,602,772 shares of the company’s stock valued at $1,245,000 after buying an additional 5,206 shares during the period. Virtu Financial LLC increased its stake in shares of Hepion Pharmaceuticals by 152.8% in the 1st quarter. Virtu Financial LLC now owns 53,501 shares of the company’s stock valued at $42,000 after buying an additional 32,336 shares during the period. Envestnet Asset Management Inc. increased its stake in shares of Hepion Pharmaceuticals by 131.9% in the 4th quarter. Envestnet Asset Management Inc. now owns 202,978 shares of the company’s stock valued at $61,000 after buying an additional 115,437 shares during the period. Finally, State Street Corp increased its stake in shares of Hepion Pharmaceuticals by 8.1% in the 1st quarter. State Street Corp now owns 348,910 shares of the company’s stock valued at $450,000 after buying an additional 26,194 shares during the period. 9.37% of the stock is owned by institutional investors and hedge funds.

Hepion Pharmaceuticals Company Profile

(Get Rating)

Hepion Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease.